CliffBio
small molecule

APIXABAN

APIXABAN

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameAPIXABAN
Active ingredientAPIXABAN
Strength2.5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2024
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.